Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Rio de Janeiro, Brasilien, 20211-030
- Novo Nordisk Investigational Site
-
-
Parana
-
Curitiba, Parana, Brasilien, 80250-060
- Novo Nordisk Investigational Site
-
-
Sao Paulo
-
Campinas, Sao Paulo, Brasilien, 13081970
- Novo Nordisk Investigational Site
-
São Paulo, Sao Paulo, Brasilien, 05403-000
- Novo Nordisk Investigational Site
-
-
-
-
-
Moscow, Den Russiske Føderation, 105077
- Novo Nordisk Investigational Site
-
Saint-Petersburg, Den Russiske Føderation, 191119
- Novo Nordisk Investigational Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85016-7710
- Novo Nordisk Investigational Site
-
-
California
-
Orange, California, Forenede Stater, 92868
- Novo Nordisk Investigational Site
-
Torrance, California, Forenede Stater, 90502-2004
- Novo Nordisk Investigational Site
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33607
- Novo Nordisk Investigational Site
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30912
- Novo Nordisk Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Novo Nordisk Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Novo Nordisk Investigational Site
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Novo Nordisk Investigational Site
-
East Lansing, Michigan, Forenede Stater, 48823
- Novo Nordisk Investigational Site
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64108-4619
- Novo Nordisk Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198-2168
- Novo Nordisk Investigational Site
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11201-5425
- Novo Nordisk Investigational Site
-
Valhalla, New York, Forenede Stater, 10595
- Novo Nordisk Investigational Site
-
-
Ohio
-
Dayton, Ohio, Forenede Stater, 45404
- Novo Nordisk Investigational Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239-3098
- Novo Nordisk Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Novo Nordisk Investigational Site
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Novo Nordisk Investigational Site
-
Houston, Texas, Forenede Stater, 77030
- Novo Nordisk Investigational Site
-
-
-
-
-
Milano, Italien, 20124
- Novo Nordisk Investigational Site
-
-
-
-
-
Shizuoka-shi, Shizuoka, Japan, 4208660
- Novo Nordisk Investigational Site
-
-
-
-
-
Adana, Kalkun, 01130
- Novo Nordisk Investigational Site
-
Antalya, Kalkun, 01010
- Novo Nordisk Investigational Site
-
Bornova-IZMIR, Kalkun, 35100
- Novo Nordisk Investigational Site
-
Izmit, Kalkun, 41380
- Novo Nordisk Investigational Site
-
-
-
-
-
Vilnius, Litauen, LT-08406
- Novo Nordisk Investigational Site
-
-
-
-
-
Skopje, Makedonien, Den Tidligere Jugoslaviske Republik, 1000
- Novo Nordisk Investigational Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 50400
- Novo Nordisk Investigational Site
-
-
-
-
-
Warszawa, Polen, 00-576
- Novo Nordisk Investigational Site
-
Wroclaw, Polen, 50-345
- Novo Nordisk Investigational Site
-
-
-
-
-
San Juan, Puerto Rico, 00935
- Novo Nordisk Investigational Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Novo Nordisk Investigational Site
-
-
-
-
-
Taipei, Taiwan, 40447
- Novo Nordisk Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male patients with severe (baseline FVIII less than or equal to 1%) haemophilia A
- Age below 12 years and weight at least 11 kg
Exclusion Criteria:
- Surgery planned to occur during trial participation (exceptions are port placement, dental extractions, and minor, uncomplicated emergent procedures)
- Congenital or acquired coagulation disorders other than haemophilia A
- Any history of FVIII inhibitors (greater than or equal to 0.6 BU/mL)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: rFVIII
|
Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa.
The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections.
The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))
Tidsramme: The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject.
|
The incidence rate of FVIII inhibitors was calculated by including all patients with inhibitors in the nominator and including all patients with a minimum 50 exposure plus any patients with less than 50 exposures but with inhibitors in denominator.
|
The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of Adverse Events (AEs)
Tidsramme: The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject
|
Adverse event was defined as events occurring after administration of trial product.
Severe AEs: considerable interference with subject's daily activities, unacceptable.
Moderate AEs: Marked symptoms, moderate interference with the patient's daily activities.
Mild AEs: No or transient symptoms, no interference with the patient's daily activities.
Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
|
The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Santagostino E, Lentz SR, Misgav M, Brand B, Chowdary P, Savic A, Kilinc Y, Amit Y, Amendola A, Solimeno LP, Saugstrup T, Matytsina I. Safety and efficacy of turoctocog alfa (NovoEight(R)) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia. 2015 Jan;21(1):34-40. doi: 10.1111/hae.12518. Epub 2014 Oct 2.
- Ozelo MC. Updates from guardian: a comprehensive registration programme. Eur J Haematol. 2015 Dec;95 Suppl 81:22-9. doi: 10.1111/ejh.12648.
- Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013 Sep;19(5):698-705. doi: 10.1111/hae.12165. Epub 2013 May 8.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NN7008-3545
- U1111-1113-7182 (Anden identifikator: WHO)
- 2009-016383-36 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .